1. Tanaka K, Aikawa Y, Kawasaki H, Asaoka K, Inaba T, Yoshida C (1992) Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 4th communication: inhibitory effect on the production of interleukin-1 and interleukin-6. Aust J Pharm 15(11):649–655
2. Tanaka K, Makino S, Shimotori T, Aikawa Y, Inaba T, Yoshida C (1992) Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4′-1-benzopyran-4-o ne. 2nd communication: effect on the arachidonic acid cascades. Arzneimittelforschung 42(7):945–950
3. Tanaka K, Shimotori T, Makino S, Aikawa Y, Inaba T, Yoshida C, Takano S (1992) Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-o ne. 1st communication: antiinflammatory, analgesic and other related properties. Arzneimittelforschung 42(7):935–944
4. Tanaka K, Shimotori T, Makino S, Eguchi M, Asaoka K, Kitamura R, Yoshida C (1992) Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 3rd communication: the involvement of bradykinin in its analgesic actions. Aust J Pharm 15(11):641–647
5. Song J, Liu H, Zhu Q, Miao Y, Wang F, Yang F, Cheng W, Xi Y, Niu X, He D, Chen G (2018) T-614 promotes Osteoblastic cell differentiation by increasing Dlx5 expression and regulating the activation of p38 and NF-kappaB. Biomed Res Int 2018:4901591–4901598. https://doi.org/10.1155/2018/4901591